Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.

Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO.

Am J Hematol. 2019 Dec;94(12):1382-1387. doi: 10.1002/ajh.25647. Epub 2019 Oct 21.

PMID:
31595538
2.

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.

Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR.

Haematologica. 2019 Dec;104(12):e555-e557. doi: 10.3324/haematol.2018.214429. Epub 2019 Apr 4. No abstract available.

3.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.

Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG.

Cancer. 2019 May 1;125(9):1470-1481. doi: 10.1002/cncr.31896. Epub 2018 Nov 30.

4.

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS.

Lancet Haematol. 2018 Nov;5(11):e532-e542. doi: 10.1016/S2352-3026(18)30156-X.

5.

Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.

Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO.

Bone Marrow Transplant. 2019 Jun;54(6):839-848. doi: 10.1038/s41409-018-0344-9. Epub 2018 Sep 26.

PMID:
30258129
6.

Is a matched unrelated donor search needed for all allogeneic transplant candidates?

Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE.

Blood Adv. 2018 Sep 11;2(17):2254-2261. doi: 10.1182/bloodadvances.2018021899.

7.

An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR.

Nat Med. 2018 Jul;24(7):1036-1046. doi: 10.1038/s41591-018-0052-4. Epub 2018 Jun 11.

PMID:
29892070
8.

Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.

Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE.

Blood. 2018 Jun 28;131(26):2989-2992. doi: 10.1182/blood-2018-02-832360. Epub 2018 May 16. No abstract available.

PMID:
29769261
9.

AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth.

Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RE, Harrington MA, Cahill CW, Bueso-Ramos C, Andreeff M.

JCI Insight. 2017 Jul 6;2(13). pii: 90036. doi: 10.1172/jci.insight.90036. eCollection 2017 Jul 6.

10.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

11.

Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.

Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH.

Eur J Haematol. 2017 Mar;98(3):263-268. doi: 10.1111/ejh.12826. Epub 2016 Dec 1.

PMID:
27862330
12.

Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation.

Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, Rezvani K, Champlin R, Ciurea SO.

Biol Blood Marrow Transplant. 2016 Mar;22(3):505-13. doi: 10.1016/j.bbmt.2015.10.020. Epub 2015 Oct 31.

13.

Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.

Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE.

Biol Blood Marrow Transplant. 2015 May;21(5):906-12. doi: 10.1016/j.bbmt.2015.01.026. Epub 2015 Feb 7.

14.

Microvasculature and healing potential of the inner versus outer preputial skin: preliminary immunohistochemical observations.

Elbakry A, Matar A, Zalata K, Zakaria A, Al Atrash G.

Int Urol Nephrol. 2015 Feb;47(2):217-22. doi: 10.1007/s11255-014-0881-0. Epub 2014 Nov 20.

PMID:
25409933
15.

Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1975-81. doi: 10.1016/j.bbmt.2014.08.013. Epub 2014 Sep 28.

16.

Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases.

Datta A, Kitson RP, Xue Y, al-Atrash G, Mazar AP, Jones TR, Goldfarb RH.

In Vivo. 2002 Nov-Dec;16(6):451-7.

PMID:
12494889
17.

IL-2-mediated upregulation of uPA and uPAR in natural killer cells.

Al-Atrash G, Shetty S, Idell S, Xue Y, Kitson RP, Halady PK, Goldfarb RH.

Biochem Biophys Res Commun. 2002 Mar 22;292(1):184-9.

PMID:
11890690
18.

uPA and uPAR contribute to NK cell invasion through the extracellular matrix.

Al-Atrash G, Kitson RP, Xue Y, Mazar AP, Kim MH, Goldfarb RH.

Anticancer Res. 2001 May-Jun;21(3B):1697-704.

PMID:
11497249
19.

Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion.

al-Atrash G, Kitson RP, Xue Y, Goldfarb RH.

In Vivo. 2000 Sep-Oct;14(5):565-70.

PMID:
11125540
20.

A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.

Goldfarb RH, Koelemij R, Muirhead KA, Ohlsson-Wilhelm BM, Gray BD, Kuppen PJ, Basse PH, al-Atrash G, Kitson RP.

In Vivo. 2000 Jan-Feb;14(1):101-4.

PMID:
10757065
21.

An axially vascularized meatal-based flap for the repair of hypospadias.

Elbakry A, Shamaa M, Al-Atrash G.

Br J Urol. 1998 Nov;82(5):698-703.

PMID:
9839586

Supplemental Content

Loading ...
Support Center